Suppr超能文献

社区获得性和医院内腹腔内感染的临床和微生物学特征:法国前瞻性观察性EBIIA研究结果

Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study.

作者信息

Montravers Philippe, Lepape Alain, Dubreuil Luc, Gauzit Rémy, Pean Yves, Benchimol Daniel, Dupont Hervé

机构信息

Département d'Anesthésie Réanimation, CHU Bichat-Claude Bernard, Assistance Publique Hôpitaux de Paris, Université Paris VII, Paris, France.

出版信息

J Antimicrob Chemother. 2009 Apr;63(4):785-94. doi: 10.1093/jac/dkp005. Epub 2009 Feb 5.

Abstract

OBJECTIVES

The EBIIA (Etude épidémiologique Bactério-clinique des Infections Intra-Abdominales) study was designed to describe the clinical, microbiological and resistance profiles of community-acquired and nosocomial intra-abdominal infections (IAIs).

PATIENTS AND METHODS

From January to July 2005, patients undergoing surgery/interventional drainage for IAIs with a positive microbiological culture were included by 25 French centres. The primary endpoint was the epidemiology of the microorganisms and their resistance to antibiotics. Multivariate analysis was carried out using stepwise logistic regression to assess the factors predictive of death during hospitalization.

RESULTS

Three hundred and thirty-one patients (234 community-acquired and 97 nosocomial) were included. The distribution of the microorganisms differed according to the type of infection. Carbapenems and amikacin were the most active agents in vitro against Enterobacteriaceae in both community-acquired and nosocomial infections. Against Pseudomonas aeruginosa, amikacin, imipenem, ceftazidime and ciprofloxacin were the most active agents in community-acquired infections, while imipenem, cefepime and amikacin were the most active in nosocomial cases. Against the Gram-positive bacteria, vancomycin and teicoplanin were the most active in both infections. Against anaerobic bacteria, the most active agents were metronidazole and carbapenems in both groups. Empirical antibiotic therapy adequately targeted the pathogens for 63% of community-acquired and 64% of nosocomial peritonitis. The presence of one or more co-morbidities [odds ratio (OR) = 3.17; P = 0.007], one or more severity criteria (OR = 4.90; P < 0.001) and generalized peritonitis (OR = 3.17; P = 0.006) were predictive of death.

CONCLUSIONS

The principal results of EBIIA are a higher diversity of microorganisms isolated in nosocomial infections and decreased susceptibility among these strains. Despite this, the adequacy of treatment is comparable in the two groups.

摘要

目的

EBIIA(腹部感染细菌临床流行病学研究)旨在描述社区获得性和医院内获得性腹腔内感染(IAIs)的临床、微生物学及耐药特征。

患者与方法

2005年1月至7月,法国25个中心纳入接受手术/介入性引流治疗且微生物培养呈阳性的IAIs患者。主要终点是微生物的流行病学及其对抗生素的耐药性。采用逐步逻辑回归进行多变量分析,以评估住院期间死亡的预测因素。

结果

共纳入331例患者(234例社区获得性感染和97例医院内获得性感染)。微生物的分布因感染类型而异。在社区获得性和医院内获得性感染中,碳青霉烯类和阿米卡星对肠杆菌科细菌的体外活性最强。对于铜绿假单胞菌,阿米卡星、亚胺培南、头孢他啶和环丙沙星在社区获得性感染中活性最强,而亚胺培南、头孢吡肟和阿米卡星在医院内感染中活性最强。对于革兰氏阳性菌,万古霉素和替考拉宁在两种感染中活性最强。对于厌氧菌,两组中活性最强的药物是甲硝唑和碳青霉烯类。经验性抗生素治疗对63%的社区获得性腹膜炎和64%的医院内获得性腹膜炎的病原体靶向治疗充分。存在一种或多种合并症[比值比(OR)=3.17;P=0.007]、一种或多种严重程度标准(OR=4.90;P<0.001)和弥漫性腹膜炎(OR=3.17;P=0.006)可预测死亡。

结论

EBIIA的主要结果是医院内感染分离出的微生物种类更多,且这些菌株的敏感性降低。尽管如此,两组的治疗充分性相当。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验